ABATACEPT IN RHEUMATOID ARTHRITIS
Journal Title: International Research Journal of Pharmacy (IRJP) - Year 2011, Vol 2, Issue 7
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, which if left untreated leads to progressive disability and joint destruction. A combination of anti-inflammatory agents, steroids, disease-modifying antirheumatic drugs (DMARDs), and biological agents are used to treat RA. Patients who fail to respond to traditional DMARDs may receive tumor necrosis factor-α (TNF-α) antagonists. However, approximately one-third of patients fail TNF-α antagonists due to adverse effects or lack of efficacy, and there are limited treatment options available to these patients. As knowledge of the underlying immunopathology of RA evolves, new strategies for inhibiting the inflammatory process have emerged. It is well known that activated T cells play a key role in orchestrating the immunopathological mechanisms of RA. Inhibiting the full activation of T cells is a rational strategy in the treatment of RA and represents a novel method of inhibiting disease activity, distinct from inflammatory cytokine blockade. Abatacept, a soluble human fusion protein that selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of rheumatoid arthritis (RA) in the United States, Canada, and the European Union. It is approved for reducing the signs and symptoms of RA, inducing major clinical response, slowing the progression of structural damage, and improving physical function in RA patients with moderate-to-severe disease who have had an inadequate response to other disease modifying, anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists.
Authors and Affiliations
Hiren Mehta , Prakash Thakkar , Manish Patel , Indermeet Anand , Paresh Patel
Keywords
Related Articles
- EP ID EP86451
- DOI -
- Views 153
- Downloads 0
TRANSCUTANEOUS DRUG DELIVERY SYSTEM: A COMPREHENSIVE REVIEW
Conventional drug delivery systems are often not suitable for new protein based and other Therapeutic compounds produced by modern technology. Therefore an alternative Approach to deliver these drugs can be achieved thro...
PHYTOCHEMICAL CONSTITUENTS AND PHARMACOLOGICAL ACTIVITIES OF ECLIPTA ALBA LINN (ASTERACEAE): A REVIEW
Eclipta alba (L.) Hassk commonly known as bhringraj. It is mainly found spreading easily in moist grounds and is widely used for its nutritional values all over the world. The plant is used to treat different diseases in...
ALLELOPATHIC EFFECTS OF WEED (Tridax procumbens L.) EXTRACT ON SEED GERMINATION AND SEEDLING GROWTH OF SOME LEGUMINOUS PLANTS
Aqueous leaves extract of different concentrations of weed (Tridax procumbens L.) was used to investigate their allelopathic effects on seed germination, root and shoot length and fresh and dry weight of some leguminous...
SYNTHESIS, CHARACTERISATION AND ANTICANCER ACTIVITY OF SCHIFF BASE DERIVATIVES OF 5-(2-PHENOXYPYRIDIN-3-YL)-1, 3, 4-THIADIAZOL-2-AMINE
Schiff Bases of 5-(2-phenoxypyridin-3-yl)-1, 3, 4-thiadiazol-2-aminederivatives 6(a-h) have been synthesized with different aromatic aldehyde and tested for in vitro anticancer activity; the 1, 3, 4-thiadiazole derivativ...
FAST DISSOLVING TABLETS: AN UPDATE
Fast dissolving tablets are dissolving rapidly in the saliva without the need for water. Some tablets are designed to dissolve in saliva remarkably fast, within a few seconds, and are true fast-dissolving tablets. Other...